New drug SGR-1505 enters human testing for blood cancers
Disease control
Recruiting now
This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia). The main goals are to check safety, find the best dose, and see how the body handles the drug. Participants must have a confirmed diagnosis and be …
Phase: PHASE1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated May 04, 2026 16:22 UTC